Revaccination with a 23-Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

作者: Susan B Manoff , Charles Liss , Michael J Caulfield , Rocio D Marchese , Jeffrey Silber

DOI: 10.1086/651131

关键词: Bacterial antigenImmunologyStreptococcus pneumoniaePneumococcal polysaccharide vaccineAntibodyImmunizationImmunoglobulin GSerotypeBiologyVaccination

摘要: BACKGROUND: Older adults are at high risk of developing invasive pneumococcal disease, but the optimal timing and number vaccine doses needed to prevent disease among this group unknown. We compared revaccination with 23-valent polysaccharide (PN23) primary vaccination for eliciting initial persistent functional antibody responses. METHODS: Subjects aged > or = 65 years were enrolled. Functional (opsonic) total immunoglobulin (Ig) G levels measured following either PN23 (n 60) 3-5 after receiving a first 60). Antibody against serotypes 4, 14, 23F was prevaccination (day 0), 30 days vaccination, 5 vaccination. RESULTS: By day 30, both induced significant increases in opsonic IgG levels. Day slightly lower not significantly different than those Year similar groups remained higher subjects. There good agreement between postvaccination CONCLUSIONS: Revaccination older comparable inducing elevated

参考文章(38)
Ken B. Waites, Kay C. Canupp, Yu-ying Chen, Michael J. DeVivo, Moon H. Nahm, Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine. Journal of Spinal Cord Medicine. ,vol. 31, pp. 53- 59 ,(2008) , 10.1080/10790268.2008.11753981
WILLIAM A. GROVE, Statistical Methods for Rates and Proportions, 2nd ed American Journal of Psychiatry. ,vol. 138, ,(1981) , 10.1176/AJP.138.12.1644-A
W. D. Sutliff, Maxwell Finland, ANTIPNEUMOCOCCIC IMMUNITY REACTIONS IN INDIVIDUALS OF DIFFERENT AGES. Journal of Experimental Medicine. ,vol. 55, pp. 837- 852 ,(1932) , 10.1084/JEM.55.6.837
Carl Spindler, Jonas Hedlund, Aftab Jasir, Birgitta Henriques Normark, Åke Örtqvist, Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden. Vaccine. ,vol. 26, pp. 5541- 5546 ,(2008) , 10.1016/J.VACCINE.2008.06.073
Maurice A. Mufson, Helen E. Krause, Gerald Schiffman, Dallas F. Hughey, Pneumococcal antibody levels one decade after immunization of healthy adults The American Journal of the Medical Sciences. ,vol. 293, pp. 279- 284 ,(1987) , 10.1097/00000441-198705000-00001
Michael Davidson, Immunogenicity of Pneumococcal Revaccination in Patients With Chronic Disease Archives of Internal Medicine. ,vol. 154, pp. 2209- 2214 ,(1994) , 10.1001/ARCHINTE.1994.00420190111013
RUSSELL L. CECIL, EFFECTS OF VERY EARLY SERUM TREATMENT IN PNEUMOCOCCUS TYPE I PNEUMONIA Journal of the American Medical Association. ,vol. 108, pp. 689- 692 ,(1937) , 10.1001/JAMA.1937.02780090001001
Maurice R. Hilleman, Alfred J. Carlson, Arlene A. McLean, Philip P. Vella, Robert E. Weibel, Allen F. Woodhour, Streptococcus pneumoniae Polysaccharide Vaccine: Age and Dose Responses, Safety, Persistence of Antibody, Revaccination, and Simultaneous Administration of Pneumococcal and Influenza Vaccines Clinical Infectious Diseases. ,vol. 3, ,(1981) , 10.1093/CLINIDS/3.SUPPLEMENT_1.S31
RICHARD V. SIMS, The Clinical Effectiveness of Pneumococcal Vaccine in the Elderly Annals of Internal Medicine. ,vol. 108, pp. 653- 657 ,(1988) , 10.7326/0003-4819-108-5-653